{'fraction_non_alphanumeric': 0.024346257889990983, 'fraction_numerical': 0.005410279531109108, 'mean_word_length': 5.032608695652174, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The expanding role of systemic treatment in non-small cell lung cancer neo-adjuvant therapy.

Lung cancer is the leading cause of cancer death worldwide. Non-small cell lung cancer (NSCLC) accounts for 80–85% of lung carcinomas. Approximately one-third of NSCLC patients are diagnosed of early-stage disease and for these patients surgery is the most effective treatment with intent to cure. However, even for those patients who undergo surgery, survival remains dismal, with more than 50% relapsing mainly at distant sites. Efforts to improve the outcome of patients with resectable NSCLC have focused on adjuvant and neoadjuvant approaches. At present adjuvant chemotherapy following complete resection could be considered standard of care in stage II-III NSCLC patients. It may be reasonable now to look again to neo-adjuvant chemotherapy to improve survival by the early treatment of micrometastatic disease. Neo-adjuvant chemotherapy followed by surgery and/or radiotherapy has become a standard approach for stage III NSCLC patients and has also been recently explored as an option in stage IB-II NSCLC.